Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression -251% Improvement Relative Risk Case 6% Huh et al. HCQ for COVID-19 PrEP Favors HCQ Favors control
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea
Huh et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041
Huh et al., Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041
Dec 2020   Source   PDF  
  All Studies   Meta
Retrospective database analysis with 17 cases for existing HCQ users and 5 severe cases, showing no significant difference for cases and higher risk for severe cases. However, HCQ users are likely systemic autoimmune disease patients and authors do not adjust for the very different baseline risk for these patients. Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri]. This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of progression, 251.0% higher, RR 3.51, p = 0.11, treatment 5 of 8 (62.5%), control 873 of 2,797 (31.2%), adjusted per study, multivariate.
risk of case, 6.0% lower, RR 0.94, p = 0.82, treatment 17 of 122 (13.9%), control 7,324 of 43,924 (16.7%), adjusted per study, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huh et al., 19 Dec 2020, retrospective, database analysis, South Korea, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Infectious Diseases 104 (2021) 7–14 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea Kyungmin Huha,1, Wonjun Jib,1, Minsun Kangc,1, Jinwook Hongc, Gi Hwan Baec , Rugyeom Leec , Yewon Nac, Jaehun Jungc,d,* a Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, South Korea Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, 21565, South Korea d Department of Preventive Medicine, Gachon University College of Medicine, Incheon, 21565, South Korea b c A R T I C L E I N F O A B S T R A C T Article history: Received 16 September 2020 Received in revised form 15 December 2020 Accepted 15 December 2020 Objectives: Concerns have been expressed that some drugs may increase susceptibility to SARS-CoV-2 infection. In contrast, other drugs have generated interest as potential therapeutic agents. Methods: All adults aged 18 years who were tested for COVID-19 were included. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later. The outcome measures were the diagnosis of COVID-19 and severe COVID-19. Disease risk score matching and multiple logistic regression was used. Results: Matched claims and testing results were available for 219,961 subjects, of whom 7,341 (3.34%) were diagnosed with COVID-19. Patients were matched to 36,705 controls, and the subset of 878 patients of severe COVID-19 also matched with 1,927 mild-to-moderate patients. Angiotensin receptor blockers were not associated with either the diagnosis of COVID-19 (adjusted OR [aOR], 1.02; 95% confidence interval [CI], 0.90–1.15) or severe disease (aOR, 1.11; 95% CI, 0.87–1.42). The use of hydroxychloroquine was not associated with a lower risk for COVID-19 (aOR, 0.94; 95% CI, 0.53–1.66) or severe disease (aOR, 3.51; 95% CI, 0.76–16.22). Conclusions: In this national claims data-based case-control study, no commonly prescribed medications were associated with risk of COVID-19 infection or COVID-19 severity. © 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( Keywords: COVID-19 Disease risk score Prophylaxis South Korea Treatment
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop